基于NLC的利芬素输送系统:开发和表征用于改善抗黄菌的药物性能
Javiera Carrasco-Rojas1, Felipe I Sandoval2, Christina M A P Schuh2
1Departamento de Ciencias y Tecnología Farmacéutica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile.
Pharmaceutics
|June 27, 2025
概括
这项研究开发了装有里芬素 (NLC-RIF) 的纳米结构脂质载体,以克服其局限性. 在保持细胞活力的同时,NLC-RIF显著增强了对 Staphylococcus aureus 的抗菌活性.
科学领域:
- 制药科学 制药科学
- 纳米技术纳米技术
- 传染性疾病 传染性疾病
背景情况:
- 里芬素对黄金菌球菌感染至关重要,但面临着溶解性和耐药性差等挑战.
- 纳米结构脂质载体 (NLCs) 是一种可行的方法来提高药物输送和疗效.
- 开发新的药物输送系统是打击抗生素耐药性的关键.
研究的目的:
- 为了制定和描述含有利芬素的NLC (NLC-RIF).
- 评估NLC-RIF.IF的体外释放动力学和抗菌功效.
- 通过细胞毒性测定来评估NLC-RIF的安全性.
主要方法:
- 使用低能耗技术的热同质化方法制备了NLC-RIF.
- 特性包括粒子大小,PDI,泽塔潜力,封装效率,稳定性和药物负载.
- 在实验室释放中,评估了对S. aureus的抗菌活性和HepG2细胞细胞毒性.
主要成果:
- NLC-RIF表现出有利的物理化学特性和良好的体稳定性.
- 药物释放遵循双相模式,与科尔斯迈耶-佩帕斯模型相一致.
- 通过NLC-RIF,显著增强了对S. aureus的有效性 (IC50 = 0.46 ng/mL),细胞毒性最小.
结论:
- NLC-RIF是一种有前途的纳米载体,可以改善利芬素的输送和抗菌功效.
- 开发的系统为利芬素提供了增强的稳定性和溶解性.
- NLC-RIF代表了一种潜在的策略,可以更有效地对抗金黄色细菌感染.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...